The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to psychedelic drug luvesilocin, from biopharmaceutical developer Reunion Neuroscience, for the treatment of postpartum depression. 

Luvesilocin is a recently-discovered proprietary psychedelic that can produce an acute subjective experience of around 3 to 4 hours shorter than that reported for some classic psychedelics such as LSD. 

It is the ninth psychedelic to receive breakthrough therapy designation by the agency, a qualification meant to to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition, when preliminary clinical evidence shows that the drug could demonstrate a substantial improvement over available therapy. 

The Trial

Postpartum depression affects a substantial portion of people who have recently given birth. Globally, the condition is estimated to occur in roughly 10 % to 20 % of postpartum women.

According to the announcement from last week, Reunion’s clinical trial achieved its primary endpoint, showing a statistically significant reduction in depression seven days after administration.¡

Participants receiving a 30mg dose showed reductions in depressive symptoms as early as Day 1 that were maintained through Day 28 of follow-up, with 70 % of those patients in remission at both Day 7 and Day 28. 

With BTD status, luvesilocin is eligible for benefits associated with the FDA’s Fast Track program and will receive enhanced guidance and engagement with senior FDA leadership.

Reunion Neuroscience has said it plans to initiate a pivotal Phase 3 trial of luvesilocin in postpartum depression in 2026. The company is also enrolling patients in a Phase 2 trial for adjustment disorder related to cancer and other medical conditions, and anticipates beginning a Phase 2 trial in generalized anxiety disorder in early 2026.

What Luvesilocin Is and How It Works

Luvesilocin belongs to a class of molecules known as substituted tryptamines. 

Tryptamines are a family of compounds derived from the amino acid tryptophan, which includes endogenous neurotransmitters like serotonin, as well as classical psychedelic agents such as psilocin and DMT. Many structurally related molecules share the same backbone and interact with serotonin receptors, producing altered perceptions and changes in mood and cognition.

Chemically, luvesilocin is a prodrug of 4-HO-DiPT, meaning the compound is metabolised in the body to release the active serotonin receptor agonist, in a similar way to how psilocybin is metabolized into psilocin, which is the active ingredient producing a psychedelic effect in humans.

The active moiety of luvesilocin, 4-HO-DiPT, itself is part of this broader class and was described in the scientific literature as early as the late 1970s. It differs slightly in structure from psilocin (the active form of psilocybin), which may influence its receptor interactions and subjective effects. 

Unlike many classic psychedelics taken orally, luvesilocin is administered via subcutaneous injection, which contributes to its more predictable and shorter duration.

Clinical updates from Compass Pathways and Helus Pharma from last week marked a significant step forward in the psychedelics development landscape, with new data emerging from late stage and mid stage programs targeting depressive disorders.

Compass reported positive results from its second Phase 3 trial of COMP360, a synthetic psilocybin therapy for treatment resistant depression, meeting the study’s primary endpoint at Week 6. The company said the 25 mg dose produced a statistically significant reduction in depressive symptoms versus a control group, with rapid onset and a safety profile consistent with earlier studies, supporting planned regulatory discussions.

Helus Pharma (formerly Cybin) reported positive results from a mid stage clinical trial of its DMT based therapy, SPL026, in people with moderate to severe depression. Participants who received the treatment showed significantly greater improvements in their symptoms than those given placebo, with effects emerging within a week and lasting for several weeks. No treatment related serious safety issues were reported.

Compass Pathways Posts Second Positive Phase 3 Result in Treatment Resistant Depression

Compass Pathways reported results from its second Phase 3 trial evaluating COMP360, a proprietary synthetic psilocybin formulation, in patients with treatment resistant depression. The study forms part of the company’s pivotal development program and follows earlier positive findings.

The company has advanced COMP360 through a development that now includes two positive Phase 3 trials in treatment resistant depression. The therapy previously received Breakthrough Therapy designation from the U.S. Food and Drug Administration and a comparable innovation pathway designation in the UK. Last month, Compass also announced an acceptance by the FDA of COMP360 for the indication of PTSD.

Recently, CEO Kabir Nath told Psychedelic Health that based on the latest stream of positive clinical results, COMP360 “could potentially be looking at a launch in early 2027,” though the psychedelics spae is still recovering from the rejection of Lykos’ MDMA application in 2024.

According to Compass, the latest trial met its primary endpoint, demonstrating a statistically significant reduction in depressive symptoms compared with control at week 6, as measured by the Montgomery Asberg Depression Rating Scale, or MADRS. Patients receiving a 25 mg dose showed a mean reduction that translated into a 3.8 point difference versus the 1 mg control group at the primary timepoint.

The antidepressant effect was observed rapidly, with separation from control evident as early as the day after administration. Treatment effects were sustained through at least six weeks. In a related Phase 3 study within the same program, a subgroup of participants maintained clinically meaningful reductions in MADRS scores through 26 weeks following one or two dosing sessions. Retreatment in eligible patients appeared to yield consistent response patterns, and no unexpected safety findings were reported across the studies.

Treatment resistant depression remains a major unmet need, defined generally as inadequate response to at least two prior antidepressant therapies. Compass has indicated that it intends to engage with the FDA to discuss next steps, including a potential rolling submission of a New Drug Application. The company has previously guided toward a possible submission timeline in late 2026, contingent on regulatory feedback and completion of required analyses.

Helus Pharma Reports Mid Stage Data Showing Rapid Symptom Improvement in Depression

In parallel, Helus Pharma, formerly known as Cybin, released detailed results from a Phase 2a randomized, placebo controlled study of SPL026, an intravenous formulation of N,N dimethyltryptamine, or DMT, in adults with moderate to severe major depressive disorder. The findings were published in the journal Nature Medicine and reflect one of the more advanced controlled studies of DMT in this indication.

The SPL026 program was previously led by the company Small Pharma, which was acquired by Cybin in 2023. Earlier this year, Cybin announced it would change its name to Helus Pharma, following a recent trend of companies in the psychedelics space rebranding to reflect a more mature subsector within biotech.

By the second week of the study, people who received SPL026 showed significantly greater improvements in their depression symptoms than those who received a placebo. On average, the difference between the two groups was clear and clinically meaningful, with an even larger gap already visible after just one week.

At Week 2, about 35 percent of participants given SPL026 experienced a marked improvement in symptoms, compared with 12 percent of those on placebo. Nearly 29 percent of treated participants saw their symptoms ease to the point of remission, versus 12 percent in the placebo group. In a follow up phase where all participants could receive the treatment, many maintained their improvements for up to three months.

The safety profile was described as manageable, with no treatment related serious adverse events reported in the study population. Acute psychedelic effects were consistent with the pharmacology of DMT and were administered in a controlled clinical setting with psychological support.

Despite the positive data, Helus has indicated that it does not plan to advance SPL026 in its current intravenous format. Instead, the company intends to use the findings to inform development of next generation short acting serotonergic agonists within its broader pipeline. Topline data from a separate Phase 2 program targeting generalized anxiety disorder are anticipated in 2026.

Together, the updates from Compass and Helus reflect continued maturation of the psychedelics field, with one company reporting confirmatory Phase 3 outcomes in treatment resistant depression and another publishing controlled mid stage data in major depressive disorder. Regulatory engagement and strategic portfolio decisions will shape the next phase of development as sponsors seek to translate controlled trial results into potential approvals and commercial pathways.

Image is an illustration made using generative AI tools.

In 2025, the psychedelic medicine sector reached a more defined phase of maturity, as Big Pharma entry, late-stage clinical readouts, and incremental regulatory shifts began to reshape investor expectations, policy debates, and the direction of research across business, government, and academia.

Business and Investment

Big Pharma joins the sector as key companies push research goals forward 

2025 saw pivotal corporate developments across the major psychedelic medicine companies, uplifting investor expectations and clarifying some regulatory pathways. A slow but steady loosening of regulatory hurdles and positive clinical results have breathed new life into the sector, with some analysts reporting refreshed investor interest and a possible end to the capital drought that has slashed the space in recent years.

Big Pharma giant AbbVie, known for blockbuster drugs in immunology and oncology, agreed to acquire Gilgamesh Pharmaceuticals’ lead experimental therapy, bretisilocin, in a deal reportedly worth $1.2 billion. Bretisilocin is a novel psychedelic targeting major depressive disorder. The event is a signal of Big Pharma entering the space and prioritising shorter-acting serotonin-2A modulators for depression.

Compass Pathways reached a major clinical inflection point, reporting positive results in its first Phase 3 COMP360 trial and accelerating commercial launch planning. CEO Kabir Nath recently told Psychedelic Health that positive talks with the FDA indicate that the company “could potentially be looking at a launch in early 2027” for its flagship program with synthetic psilocybin.

Beckley Psytech, which is supported by Atai Life Sciences secured a Breakthrough Therapy designation by the FDA for BPL-003, a novel intranasal formulation of 5-MeO-DMT, reinforcing regulatory momentum the compound known as “toad venom.” The FDA’s decision follows promising results from a Phase 2b clinical trial, which demonstrated that a single dose of the compound led to rapid and sustained reductions in depressive symptoms within 24 hours, with effects lasting up to eight weeks.

Cybin advanced multiple clinical programs, completing enrollment milestones for CYB004, a version of DMT targeting generalised anxiety disorder and maintaining progress on CYB003, a 5-HT2A receptor agonist similar to psilocybin for major depressive disorder. The company secured financing to extend runway and protect intellectual property across its portfolio.

MindMed reported faster than expected enrollment in its Phase 3 MM120 program, an analog of LSD targeting generalised anxiety disorder, updating timelines for topline readouts and emphasising oral LSD analogs as a differentiated regulatory route. 

Policy and Regulation

Major global players reschedule psychedelics for medical use

2025 marked a year of uneven but consequential movement in psychedelic policy and regulation, with a small number of jurisdictions taking concrete steps toward medical access while others remained in exploratory or preparatory phases.

The UK’s regulatory landscape for psychedelic medicine continued to evolve through policy dialogue and research initiatives, although no formal legalisation or medical scheduling changes occurred. The Royal College of Psychiatrists published a position statement reviewing evidence on psilocybin, MDMA, LSD, and ketamine, concluding that current data are promising but insufficient to recommend routine clinical use outside licensed settings, emphasising the need for more robust trials and caution against premature adoption.

This year, the UK government agreed in principle with key Advisory Council on the Misuse of Drugs (ACMD) recommendations to ease barriers to Schedule 1 psychedelic research. Part of the recommendations included allowing universities and hospitals to conduct research without a Home Office domestic licence, and ethically approved clinical trials to be exempt from additional licensing. Though these changes are not in effect yet, they could be enacted after a pilot program takes place.

Australia continued to stand out as a global pioneer in medical access. Since 1 July 2023, MDMA and psilocybin have been rescheduled from strictly prohibited status to controlled medicines, meaning authorised psychiatrists can legally prescribe them for treatment-resistant depression and post-traumatic stress disorder. From 6 January 2025, new quality standards for MDMA and psilocybin products came into force, requiring compliance for all supplied APIs and finished products. The Department of Veterans’ Affairs approved funding for psychedelic-assisted psychotherapy for eligible veterans, marking a first step toward public payer support.

In Europe, Germany became the first EU country to establish a formal compassionate use access programme for psilocybin, enabling adults with treatment-resistant depression to receive psilocybin therapy at specialised centres under a regulated framework prior to full regulatory approval. This initiative, supported by the German Federal Institute for Drugs and Medical Devices and implemented at facilities in Mannheim and Berlin, marks a landmark step in European psychedelic policy.

The Czech Republic is set to become one of the first European countries to legalise medical use of psilocybin from January 1, 2026. The outgoing government approved legislation late in 2025 allowing psychiatrists and psychotherapists to administer psilocybin for conditions such as cancer-related depression and serious clinical depression when other registered treatments have failed or are not tolerated. Psilocybin therapy will be introduced under controlled clinical conditions at qualified facilities.

In the United States, action remained at the state-level. Oregon and Colorado, having already legalised regulated access to natural psychedelics including psilocybin and launched supervised service programs, continued to refine implementation and data collection frameworks in 2025. Meanwhile, numerous state legislatures introduced bills to advance psychedelic therapy access, and Massachusetts held legislative hearings on psychedelic therapy programmes, reflecting growing political engagement despite the absence of federal reclassification.

Science and Research

New data from real-world applications and feedback from regulatory agencies inform research 

In the academic side of the equation, 2025 consolidated a transition from exploratory efficacy signals to confirmatory, regulation-relevant evidence, while underscoring persistent limitations: small sample biases, variable control conditions, and unresolved questions about long-term safety and scalability.

One of the most significant published findings came from a phase 2 trial in cancer patients, where a single dose of psilocybin combined with therapy produced sustained reductions in depression and anxiety, with many participants maintaining benefits up to two years later. 

Alongside observational outcomes, mid-stage clinical studies have found LSD may ease anxiety symptoms for up to three months in people with moderate-to-severe generalised anxiety disorder, with a significant proportion of participants still in remission at 12 weeks.

For the first time, data from real-world application of psilocybin treatment under a regulated program was published by one of the Oregon clinics providing treatment, sharing insights into how the legal, real-world version of the treatment works, who can access it, and whether the benefits observed in trials translate to broader populations.

Longitudinal data strengthened claims of sustained benefit in selected cohorts. Multiple follow-up reports published in 2025 described durable antidepressant effects at extended intervals after single or limited psilocybin administrations, although most samples remained small and non-randomised. These findings have prompted calls for larger, controlled long-term studies. 

The FDA’s public release of the complete response letter on Lykos Therapeutics’ trials on MDMA therapy highlighted durability and safety questions, prompting re-examination of trial design and participant selection in MDMA and related programmes.

Cambridge Psychedelic Research Group formally launched in 2025, creating a new hub for clinical trials and interdisciplinary research in the UK, including pathways for patient recruitment and academic-industry collaboration.

Illustrated image made using AI tools.